Superinfection

Cinesteam® Is Restoring Quality of Life in Cancer Patients

Retrieved on: 
Tuesday, October 24, 2023

FORT LAUDERDALE, Fla., Oct. 24, 2023 /PRNewswire/ -- The fight against cancer is a heavy burden. As patients seek healing and undergo serious and aggressive treatments, the last thing they need is additional concerns weighing them down. And yet, that is precisely what happens when ongoing cancer treatment leads to the formation of malodorous wounds.

Key Points: 
  • These Malodorous Wounds Detract From Quality of Life and Add Unnecessary Emotional and Mental Strain.
  • As patients seek healing and undergo serious and aggressive treatments, the last thing they need is additional concerns weighing them down.
  • One study reports that malodorous smells in cancer patients can come from one of three sources:
    Necrosis: The decomposition of dead tissue.
  • Cinesteam® removes that barrier and enables those in cancer treatment to regain a sense of confidence, self-esteem, and quality of life as they look to get the most out of each day."

Vir Biotechnology Announces First Patient Dosed in the Phase 2 SOLSTICE Trial Evaluating VIR-2218 and VIR-3434 for the Treatment of Chronic Hepatitis D Virus Infection

Retrieved on: 
Thursday, September 22, 2022

SAN FRANCISCO, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the first patient has been dosed in the Phase 2 SOLSTICE clinical trial evaluating VIR-2218 and VIR-3434 as monotherapy and in combination for the treatment of people living with chronic hepatitis D virus (HDV), which occurs as a simultaneous co-infection or super-infection alongside hepatitis B virus (HBV). HDV infection, the most aggressive form of viral hepatitis, increases the risk of poor outcomes, including liver cancer and death, compared with HBV alone.

Key Points: 
  • VIR-2218 and VIR-3434 are currently being evaluated for the treatment of HBV in the Phase 2 MARCH (Monoclonal Antibody siRNA Combination against Hepatitis B) trial.
  • Chronic hepatitis D virus (HDV) infection occurs as a simultaneous co-infection or super-infection with hepatitis B virus (HBV).
  • Chronic hepatitis B virus (HBV) infection remains an urgent global public health challenge associated with significant morbidity and mortality.
  • Its current development pipeline consists of product candidates targeting COVID-19, hepatitis B and hepatitis D viruses, influenza A and human immunodeficiency virus.

Vir Biotechnology Announces New Data From the MARCH Hepatitis B Trial, Unveils New Hepatitis D Clinical Program and Highlights Broad Hepatitis Portfolio at Virtual Hepatitis Portfolio R&D Day

Retrieved on: 
Wednesday, April 27, 2022

SAN FRANCISCO, April 27, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the Company will review its robust hepatitis portfolio, including initial data from the first cohort of the MARCH (Monoclonal Antibody siRNA Combination against Hepatitis B) trial evaluating VIR-2218 in combination with VIR-3434, as well as a new program aimed at chronic hepatitis D. Details will be discussed today at 12:00 pm ET / 9:00 am PT during Vir’s virtual Hepatitis Portfolio R&D Day.

Key Points: 
  • The Company recently sponsored a Nature Outlook Supplement titled The Push to Eliminate a Viral Liver Disease.
  • Chronic hepatitis B virus (HBV) infection remains an urgent global public health challenge associated with significant morbidity and mortality.
  • Vir Biotechnologyis a commercial-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases.
  • Its current development pipeline consists of product candidates targeting COVID-19, hepatitis B virus, influenza A and human immunodeficiency virus.

ContraFect Initiates Expanded Access to Exebacase for the Treatment of MRSA Bloodstream Infections in COVID-19 Patients

Retrieved on: 
Monday, October 26, 2020

Exebacase has been granted Breakthrough Therapy designation for the treatment of MRSA bloodstream infections by the U.S. Food and Drug Administration (FDA).

Key Points: 
  • Exebacase has been granted Breakthrough Therapy designation for the treatment of MRSA bloodstream infections by the U.S. Food and Drug Administration (FDA).
  • Exebacase has the potential to treat MRSA superinfections in patients infected with COVID-19, a significant cause of severe disease.
  • Respiratory viral infections, such as influenza, SARS and MERS, are commonly associated with secondary infections, or superinfections, by opportunistic pathogens.
  • Staph aureus is one of the most common pathogenic causes of secondary bacterial infections in patients suffering from severe respiratory viral infections.